-
1
-
-
0030892234
-
Apoptosis by death factor
-
10.1016/S0092-8674(00)81874-7, 9039262
-
Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365. 10.1016/S0092-8674(00)81874-7, 9039262.
-
(1997)
Cell
, vol.88
, pp. 355-365
-
-
Nagata, S.1
-
2
-
-
10744220151
-
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
-
10.1084/jem.20031457, 2211825, 14769851
-
Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004, 199:437-448. 10.1084/jem.20031457, 2211825, 14769851.
-
(2004)
J Exp Med
, vol.199
, pp. 437-448
-
-
Takeda, K.1
Yamaguchi, N.2
Akiba, H.3
Kojima, Y.4
Hayakawa, Y.5
Tanner, J.E.6
Sayers, T.J.7
Seki, N.8
Okumura, K.9
Yagita, H.10
Smyth, M.J.11
-
3
-
-
0032896709
-
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
-
10.1038/5505, 10229232
-
French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999, 5:548-553. 10.1038/5505, 10229232.
-
(1999)
Nat Med
, vol.5
, pp. 548-553
-
-
French, R.R.1
Chan, H.T.2
Tutt, A.L.3
Glennie, M.J.4
-
4
-
-
0344247505
-
CDNA sequences of two inducible T-cell genes
-
10.1073/pnas.86.6.1963, 286825, 2784565
-
Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989, 86:1963-1967. 10.1073/pnas.86.6.1963, 286825, 2784565.
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, pp. 1963-1967
-
-
Kwon, B.S.1
Weissman, S.M.2
-
5
-
-
0033137063
-
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
-
Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999, 162:5037-5040.
-
(1999)
J Immunol
, vol.162
, pp. 5037-5040
-
-
Takahashi, C.1
Mittler, R.S.2
Vella, A.T.3
-
6
-
-
0037094139
-
4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function
-
Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002, 168:4897-4906.
-
(2002)
J Immunol
, vol.168
, pp. 4897-4906
-
-
Wen, T.1
Bukczynski, J.2
Watts, T.H.3
-
7
-
-
58149232585
-
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma
-
10.1158/1078-0432.CCR-08-0285, 2583963, 18980984
-
Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazon A, Azpilikueta A, Ochoa MC, Alfaro C, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008, 14:6895-6906. 10.1158/1078-0432.CCR-08-0285, 2583963, 18980984.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6895-6906
-
-
Murillo, O.1
Arina, A.2
Hervas-Stubbs, S.3
Gupta, A.4
McCluskey, B.5
Dubrot, J.6
Palazon, A.7
Azpilikueta, A.8
Ochoa, M.C.9
Alfaro, C.10
-
8
-
-
70349334508
-
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
-
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. J Clin Oncol 2009,
-
(2009)
J Clin Oncol
-
-
Advani, R.1
Forero-Torres, A.2
Furman, R.R.3
Rosenblatt, J.D.4
Younes, A.5
Ren, H.6
Harrop, K.7
Whiting, N.8
Drachman, J.G.9
-
9
-
-
45649084324
-
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
-
10.1016/j.lungcan.2007.12.011, 18255187
-
Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90. 10.1016/j.lungcan.2007.12.011, 18255187.
-
(2008)
Lung Cancer
, vol.61
, pp. 82-90
-
-
Greco, F.A.1
Bonomi, P.2
Crawford, J.3
Kelly, K.4
Oh, Y.5
Halpern, W.6
Lo, L.7
Gallant, G.8
Klein, J.9
-
10
-
-
50349092260
-
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
-
10.1158/1078-0432.CCR-07-1416, 18519776
-
Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3450-3455. 10.1158/1078-0432.CCR-07-1416, 18519776.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3450-3455
-
-
Hotte, S.J.1
Hirte, H.W.2
Chen, E.X.3
Siu, L.L.4
Le, L.H.5
Corey, A.6
Iacobucci, A.7
MacLean, M.8
Lo, L.9
Fox, N.L.10
Oza, A.M.11
-
11
-
-
69949110775
-
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study
-
10.1158/1078-0432.CCR-09-0996, 19690193
-
Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009, 15:5584-5590. 10.1158/1078-0432.CCR-09-0996, 19690193.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5584-5590
-
-
Mom, C.H.1
Verweij, J.2
Oldenhuis, C.N.3
Gietema, J.A.4
Fox, N.L.5
Miceli, R.6
Eskens, F.A.7
Loos, W.J.8
de Vries, E.G.9
Sleijfer, S.10
-
12
-
-
70349318434
-
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
-
Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, et al. Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. J Clin Oncol 2009,
-
(2009)
J Clin Oncol
-
-
Leong, S.1
Cohen, R.B.2
Gustafson, D.L.3
Langer, C.J.4
Camidge, D.R.5
Padavic, K.6
Gore, L.7
Smith, M.8
Chow, L.Q.9
von Mehren, M.10
-
13
-
-
33744987907
-
Eradication of established tumors in mice by a combination antibody-based therapy
-
10.1038/nm1405, 16680149
-
Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006, 12:693-698. 10.1038/nm1405, 16680149.
-
(2006)
Nat Med
, vol.12
, pp. 693-698
-
-
Uno, T.1
Takeda, K.2
Kojima, Y.3
Yoshizawa, H.4
Akiba, H.5
Mittler, R.S.6
Gejyo, F.7
Okumura, K.8
Yagita, H.9
Smyth, M.J.10
-
14
-
-
34547628869
-
Combined natural killer T-cell based immunotherapy eradicates established tumors in mice
-
10.1158/0008-5472.CAN-07-0941, 17671220
-
Teng MW, Westwood JA, Darcy PK, Sharkey J, Tsuji M, Franck RW, Porcelli SA, Besra GS, Takeda K, Yagita H, et al. Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. Cancer Res 2007, 67:7495-7504. 10.1158/0008-5472.CAN-07-0941, 17671220.
-
(2007)
Cancer Res
, vol.67
, pp. 7495-7504
-
-
Teng, M.W.1
Westwood, J.A.2
Darcy, P.K.3
Sharkey, J.4
Tsuji, M.5
Franck, R.W.6
Porcelli, S.A.7
Besra, G.S.8
Takeda, K.9
Yagita, H.10
-
15
-
-
42349109600
-
Interleukin 21 enhances antibody-mediated tumor rejection
-
10.1158/0008-5472.CAN-07-6019, 18413772
-
Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008, 68:3019-3025. 10.1158/0008-5472.CAN-07-6019, 18413772.
-
(2008)
Cancer Res
, vol.68
, pp. 3019-3025
-
-
Smyth, M.J.1
Teng, M.W.2
Sharkey, J.3
Westwood, J.A.4
Haynes, N.M.5
Yagita, H.6
Takeda, K.7
Sivakumar, P.V.8
Kershaw, M.H.9
-
17
-
-
68149132103
-
CD1d-based combination therapy eradicates established tumors in mice
-
10.4049/jimmunol.0900796, 19620318
-
Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. CD1d-based combination therapy eradicates established tumors in mice. J Immunol 2009, 183:1911-1920. 10.4049/jimmunol.0900796, 19620318.
-
(2009)
J Immunol
, vol.183
, pp. 1911-1920
-
-
Teng, M.W.1
Sharkey, J.2
McLaughlin, N.M.3
Exley, M.A.4
Smyth, M.J.5
-
18
-
-
70349170354
-
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth
-
10.1371/journal.pone.0006982, 2734989, 19746156
-
Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009, 4:e6982. 10.1371/journal.pone.0006982, 2734989, 19746156.
-
(2009)
PLoS One
, vol.4
-
-
Most, R.G.1
Currie, A.J.2
Cleaver, A.L.3
Salmons, J.4
Nowak, A.K.5
Mahendran, S.6
Larma, I.7
Prosser, A.8
Robinson, B.W.9
Smyth, M.J.10
-
19
-
-
73349142317
-
Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice
-
10.1158/1078-0432.CCR-09-2201, 19996209
-
Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH. Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res 2009, 15:7624-7633. 10.1158/1078-0432.CCR-09-2201, 19996209.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7624-7633
-
-
Westwood, J.A.1
Haynes, N.M.2
Sharkey, J.3
McLaughlin, N.4
Pegram, H.J.5
Schwendener, R.A.6
Smyth, M.J.7
Darcy, P.K.8
Kershaw, M.H.9
-
20
-
-
73349133743
-
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
-
10.1073/pnas.0909474106, 2773732, 19892741
-
Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA 2009, 106:19455-19460. 10.1073/pnas.0909474106, 2773732, 19892741.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 19455-19460
-
-
Weiss, J.M.1
Back, T.C.2
Scarzello, A.J.3
Subleski, J.J.4
Hall, V.L.5
Stauffer, J.K.6
Chen, X.7
Micic, D.8
Alderson, K.9
Murphy, W.J.10
Wiltrout, R.H.11
-
21
-
-
0034946808
-
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
-
209333, 11435457
-
Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001, 108:51-62. 209333, 11435457.
-
(2001)
J Clin Invest
, vol.108
, pp. 51-62
-
-
Wigginton, J.M.1
Gruys, E.2
Geiselhart, L.3
Subleski, J.4
Komschlies, K.L.5
Park, J.W.6
Wiltrout, T.A.7
Nagashima, K.8
Back, T.C.9
Wiltrout, R.H.10
-
22
-
-
0022473607
-
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
-
10.1126/science.3489291, 3489291
-
Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321. 10.1126/science.3489291, 3489291.
-
(1986)
Science
, vol.233
, pp. 1318-1321
-
-
Rosenberg, S.A.1
Spiess, P.2
Lafreniere, R.3
-
23
-
-
10744226452
-
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
-
10.1073/pnas.0307298101, 357036, 14762166
-
Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004, 101:1969-1974. 10.1073/pnas.0307298101, 357036, 14762166.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 1969-1974
-
-
Klebanoff, C.A.1
Finkelstein, S.E.2
Surman, D.R.3
Lichtman, M.K.4
Gattinoni, L.5
Theoret, M.R.6
Grewal, N.7
Spiess, P.J.8
Antony, P.A.9
Palmer, D.C.10
-
24
-
-
0026033391
-
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo
-
10.1002/eji.1830210350, 2009918
-
Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991, 21:851-854. 10.1002/eji.1830210350, 2009918.
-
(1991)
Eur J Immunol
, vol.21
, pp. 851-854
-
-
Ley, V.1
Langlade-Demoyen, P.2
Kourilsky, P.3
Larsson-Sciard, E.L.4
-
25
-
-
30744458573
-
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells
-
10.1038/nm1312, 16227988
-
Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005, 11:1238-1243. 10.1038/nm1312, 16227988.
-
(2005)
Nat Med
, vol.11
, pp. 1238-1243
-
-
Zhang, H.1
Chua, K.S.2
Guimond, M.3
Kapoor, V.4
Brown, M.V.5
Fleisher, T.A.6
Long, L.M.7
Bernstein, D.8
Hill, B.J.9
Douek, D.C.10
|